ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / IBO / news
ACET (32) IXHL (37) ALDX (39) NNVC (37) ⌘ Pro Terminal →

Why IBO Stock surged +5.53% Today — RQD Quant Desk Flash

$4.01 +5.53% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.04

Impact BioMedical Inc. (IBO) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $32.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IBO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IBO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Impact BioMedical Inc. (NYSE: IBO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $4.01 (+5.53% 1D, market cap $32.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, IBO ranks #809 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IBO compare to ACET and IXHL in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IBO carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -27.5%. By comparison, ACET (Adicet Bio Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $32.0M) and IXHL (Incannex Healthcare Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $31.6M). Among the 5-stock peer group, IBO leads on earnings multiple (N/A) while IBO leads on capital efficiency (-27.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IBO?
▼

Per IBO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001834105), Impact BioMedical Inc. generated $32.0K in revenue (-100.0% YoY), -$11.8M in net income, and -$1.9M in free cash flow against $17.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $4.04 (+0.81%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510030
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (7)Whales (3)SEC (11)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.7% Base Target
$11 Bull$4 Base$3 Bear
📬 FREE IBO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IBO)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY IBO SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (37% of score)

Altman Z-Score 5.88 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 0% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
22
Grade E$3.98-17.8% Next Q
Q2 (-2Q)
25
Grade E$3.27+8.6% Next Q
Q3 (-1Q)
27
Grade E$3.55+13% Next Q
Current
30
Grade E$4.01-9.6% Hist 90D α
Trajectory: E (22) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IBO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IBO currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.09) and Max Pain ($4.21) forces dealer call-delta covering toward $11.04.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IBO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IBO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 30%NO 70%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why IBO Stock surged +5.53% Today — RQD Quant Desk Flash

Impact BioMedical Inc. (IBO) surged +5.53% to $4.01, trading at 20% of its 52-week range ($2.43 – $10.51). Stretched risk/reward at current multiples (-28% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 20% of its 52-week range ($2.43 – $10.51) with RSI-14 at 43.6 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $4.01 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 0% gross margin and $0 annual free cash flow.
Live IBO Headlines & Catalysts
MARKET WIREYahoo Finance Australia • 1d ago
Stock splits calendar for:

Yahoo Finance Australia report covering Impact BioMedical Inc. (IBO) market action, institutional positioning, and fundamental catalysts.

MARKET WIRETradingKey • 1d ago
Most Active Stocks Today: U.S. Market

TradingKey report covering Impact BioMedical Inc. (IBO) market action, institutional positioning, and fundamental catalysts.

MARKET WIREBenzinga • 19d ago
12 Health Care Stocks Moving In Thursday's Intraday Session

Gainers Regencell Bioscience (NASDAQ:RGC) stock increased by 30.4% to $10.58 during Thursday's regular session. The company's market cap stands at $4.0 billion. SenesTech (NASDAQ:SNES) stock rose 24.93% to

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IBO)

  • ✓Walkthrough of IBO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
IBO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -50.12%📐 HORIZONTAL RANGE
2026-11-03O $3.87H $4.01L $3.80C $4.01VOL 15.3K
RES: $8.27SUP: $1.95SMA50: $5.09SMA200: $6.26
$8.76$7.05$5.33$3.61$1.90RES $8.27SUP $1.95$4.012026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IBO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IBO Butterfly Map → + Track IBO →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -100.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on IBO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IBO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IBO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IBO)

Health Care Rank #809 of 1015 ⚔️ ACET vs IBO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IBO vs. ACET, IXHL, ALDX, NNVC)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Impact BioMedical Inc. (IBO) ranks #809 by composite RQD confidence (30/100, grade E) and #787 by equity capitalization ($32.5M). Within this direct 5-issuer industry benchmark cohort, IBO leads on earnings valuation at N/A trailing P/E, while IBO leads on capital efficiency and profitability with -27.5% ROIC and -30.0% gross margin. ALDX currently holds the highest overall quantitative score in the immediate peer group at 39/100 (D-) compared with IBO at 30/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
IBO ACTIVE
Impact BioMedical Inc.
E 30/100 — -30.0% -27.5% +5.53% $32.5M Benchmark Subject
ACET
Adicet Bio Inc.
E 32/100 — — -35.0% -6.43% $32.0M /acet-vs-ibo →
IXHL
Incannex Healthcare Inc.
D- 37/100 — — -35.0% -5.56% $31.6M /ixhl-vs-ibo →
ALDX
Aldeyra Therapeutics Inc.
D- 39/100 — — -35.0% +4.09% $33.8M /aldx-vs-ibo →
NNVC
NanoViricides Inc.
D- 37/100 — — -35.0% +1.50% $34.0M /nnvc-vs-ibo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001834105 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Impact BioMedical Inc. (IBO) reported GAAP revenue of $32.0K (-100.0% vs. FY2024 revenue of $80.5M , and -99.7% cumulative change since FY2023) , GAAP net income of -$11.8M, operating cash flow of -$1.9M, and free cash flow of -$1.9M (+33.8% YoY). On the balance sheet, IBO closed FY2025 with $17.4M in total assets against $0 in total debt (Altman Z-Score: 5.88, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $32.0K -$11.8M -$1.9M -$1.9M $17.4M —
FY2024 (FY) 2024-12-31 $80.5M -$24.7M -$2.9M -$2.9M $20.3M —
FY2023 (FY) 2023-12-31 $11.3M -$4.3M -$2.9M -$2.9M — —

3. IBO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IBO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Impact BioMedical Inc. (NYSE: IBO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $4.01 (+5.53% 1D, market cap $32.5M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, IBO ranks #809 in composite RQD confidence.

How does IBO compare to ACET and IXHL in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IBO carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -27.5%. By comparison, ACET (Adicet Bio Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $32.0M) and IXHL (Incannex Healthcare Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $31.6M). Among the 5-stock peer group, IBO leads on earnings multiple (N/A) while IBO leads on capital efficiency (-27.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IBO?

Per IBO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001834105), Impact BioMedical Inc. generated $32.0K in revenue (-100.0% YoY), -$11.8M in net income, and -$1.9M in free cash flow against $17.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IBO trading relative to its 50-day, 200-day, and 52-week technical levels?

IBO last traded at $4.01 (+5.53% on volume of 20,647 shares), positioning the stock -21.22% below its 50-day simple moving average ($5.09) and -35.94% below its 200-day simple moving average ($6.26). Across its 52-week range of $2.43 to $10.51, IBO sits at the 19.6% percentile with a 14-day RSI of 43.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.51 to $4.51).

Direct Sub-Reports: IBO RQD Cockpit IBO 12M Forecast IBO Earnings & Move IBO Dividends & DRIP IBO Insiders & 13F IBO Whale Options IBO Profit Sankey IBO News & Why
ROARABLE RATING BRIEF • RQD 30/100 (E) ✓ SEC XBRL & RQD VERIFIED

IBO — Impact BioMedical Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Impact BioMedical Inc. (IBO) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $4.01 (+5.53% 1D, market capitalization $32.5M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -27.5%, gross margin of -30.0%, operating margin of -60.0%, and free cash flow yield of -5.72%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (11/20): Incorporates a 1.00x equity beta, Altman Z-Score of 5.88, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Impact BioMedical Inc. Is listed on the NYSE under the ticker IBO and is classified in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry. The profile does not describe its specific products, customers, or revenue model. The reported revenue of — across the disclosed periods indicates no revenue was recognized in the SEC financials provided.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Impact BioMedical Inc. (IBO) reported $32.0K in annual revenue (up from $80.5M in FY2024, -100.0% YoY) and -$11.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($11.3M revenue, -$4.3M net income) through FY2025, IBO scaled operating cash flow to -$1.9M and free cash flow to -$1.9M, backed by $17.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 30/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -5.72% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $2.43 – $10.51 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream dependencies, downstream customers, and sector correlations therefore cannot be mapped from the source data. The graph's sector and industry classification (Health Care; Biotechnology: Pharmaceutical Preparations) is the only contextual information provided.

  • Key Question #1: Can IBO sustain or expand its -60.0% operating margin and -27.5% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $32.0K and free cash flow of -$1.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is IBO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

IBO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Impact BioMedical Inc. (IBO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IBO Debate Forum (3) ↓
🟡 MARKET WIRE Yahoo Finance Australia • 1d ago
Stock splits calendar for:

Yahoo Finance Australia report covering Impact BioMedical Inc. (IBO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IBO Bull vs. Bear Conversation Board — What's Your Call at $4.01?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IBO 🐻 33% BEARISH CONVICTION
1. Pick Your Side on IBO:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $4.98 (+31.1%)
📌 Pinned Debate

The Altman Z-Score of 5.88 is the strongest forensic datapoint in the RQD rating, indicating a comparatively favorable balance-sheet ri

Don't sleep on IBO's setup in Health Care. The Altman Z-Score of 5.88 is the strongest forensic datapoint in the RQD rating, indicating a comparatively favorable balance-sheet risk reading alongside Debt/Equity of 0.5.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (30/100) backs up the fundamental quality.

RetailWhale_TX 🐂 BULL

Both sides have a point here — IBO's 11/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $3.27 (-13.9%)
Spot @ $3.80

ROIC of -27.5%, FCF yield of -5.72%, and operating losses in every reported period show the business is not yet generating cash from it

Fading this rally in IBO at $3.80. ROIC of -27.5%, FCF yield of -5.72%, and operating losses in every reported period show the business is not yet generating cash from its capital base.. With a beta of 1.0 and the stock sitting at $3.80 (52-wk range $2.43–$10.51), the easy multiple expansion is already priced in.

LIVE TAPE